BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16461038)

  • 1. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
    Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
    Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
    Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
    Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
    Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
    Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation.
    Wolfram RM; Brewer HB; Xue Z; Satler LF; Pichard AD; Kent KM; Waksman R
    Am J Cardiol; 2006 Sep; 98(6):711-7. PubMed ID: 16950168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
    Goldenberg I; Benderly M; Goldbourt U;
    J Am Coll Cardiol; 2008 Jan; 51(4):459-65. PubMed ID: 18222357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
    Brodov Y; Behar S; Boyko V; Chouraqui P
    Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study.
    Haim M; Boyko V; Goldbourt U; Battler A; Behar S
    Arch Intern Med; 2004 Feb; 164(4):433-9. PubMed ID: 14980995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.
    Haim M; Benderly M; Tanne D; Matas Z; Boyko V; Fisman EZ; Tenenbaum A; Zimmlichman R; Battler A; Goldbourt U; Behar S
    Am Heart J; 2007 Dec; 154(6):1095-101. PubMed ID: 18035081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
    Tenenbaum A; Motro M; Fisman EZ; Tanne D; Boyko V; Behar S
    Arch Intern Med; 2005 May; 165(10):1154-60. PubMed ID: 15911729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
    Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
    Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study).
    Brodov Y; Behar S; Goldenberg I; Boyko V; Chouraqui P
    Am J Cardiol; 2009 Jul; 104(2):194-8. PubMed ID: 19576345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of high-density lipoprotein cholesterol to mortality after percutaneous coronary interventions in patients with low-density lipoprotein <70 mg/dl.
    Kini AS; Muntner P; Moreno PR; Mann D; Krishnan P; Kim MC; Rafael OC; Farkouh ME; Sharma SK
    Am J Cardiol; 2009 Feb; 103(3):350-4. PubMed ID: 19166688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of restenosis by bezafibrate after successful coronary angioplasty.
    Ishiwata S; Nakanishi S; Nishiyama S; Seki A
    Coron Artery Dis; 1995 Nov; 6(11):883-9. PubMed ID: 8696533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bezafibrate on low levels of high density lipoprotein cholesterol in normolipidemia. Study in coronary patients and their first degree relatives.
    Neuman J; Neuman MP; Di Biase L
    Arzneimittelforschung; 1986 Nov; 36(11):1690-3. PubMed ID: 3814229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age.
    Weverling-Rijnsburger AW; Jonkers IJ; van Exel E; Gussekloo J; Westendorp RG
    Arch Intern Med; 2003 Jul; 163(13):1549-54. PubMed ID: 12860577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of bezafibrate in isolated hypercholesterolemia and mixed hyperlipidemia on infarct risk (Stepwise Program for Individual Risk Identification and Therapy): an open multicenter study].
    Sinzinger H; Virgolini I; Kudlacek P
    Wien Klin Wochenschr; 1991; 103(13):381-7. PubMed ID: 1897230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
    Ericsson CG
    Eur Heart J; 1998 Jul; 19 Suppl H():H37-41. PubMed ID: 9717064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoproteins and long-term prognosis in coronary heart disease patients.
    Benderly M; Boyko V; Goldbourt U
    Am Heart J; 2009 Jan; 157(1):103-10. PubMed ID: 19081405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triglycerides + high-density-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the CArdiovascular STudy in the ELderly.
    Mazza A; Tikhonoff V; Schiavon L; Casiglia E
    Intern Med J; 2005 Oct; 35(10):604-10. PubMed ID: 16207260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.